Search Results - "Shangguan, Chengfang"

LncRNA HCP5 Participates in the Tregs Functions in Allergic Rhinitis and Drives Airway Mucosal Inflammatory Response in the Nasal Epithelial Cells by Yang, Chen, Shangguan, Chengfang, Cai, Changing, Xu, Jing, Qian, Xiaohua

“…Allergic rhinitis (AR) is an allergic disease characterized as (immunoglobulin, IgE)-mediated type I hypersensitivity disorder. Regulatory T cells (Tregs) play…”
Get full text

Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells by Jiang, Xinyi, Lin, Jian, Shangguan, Chengfang, Wang, Xiaoyao, Xiang, Bin, Chen, Juan, Guo, Hezhou, Zhang, Wu, Zhang, Jun, Shi, Yan, Zhu, Jiang, Yang, Hui

“…Antitumor activity of CD8+ T cells is potentially restrained by a variety of negative regulatory pathways that are triggered in the tumor microenvironment,…”
Get full text

Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT by Shangguan, Chengfang, Gan, Guifang, Zhang, Jieying, Wu, Jinliang, Miao, Ying, Zhang, Miao, Li, Biao, Mi, Jun

“…Purpose: Elevated glucose uptake is a hallmark of cancer. Fluorodeoxyglucose (FDG) uptake was believed to indicate the aggressiveness of tumors and the…”
Get full text

Performance of 18F-FDG PET/CT Radiomics for Predicting EGFR Mutation Status in Patients With Non-Small Cell Lung Cancer by Zhang, Min, Bao, Yiming, Rui, Weiwei, Shangguan, Chengfang, Liu, Jiajun, Xu, Jianwei, Lin, Xiaozhu, Zhang, Miao, Huang, Xinyun, Zhou, Yilei, Qu, Qian, Meng, Hongping, Qian, Dahong, Li, Biao

“…OBJECTIVETo assess the performance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) radiomics features…”
Get full text

Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA by Xi, Wenqi, Zhou, Chenfei, Xu, Fei, Sun, Debin, Wang, Shengzhou, Chen, Yawei, Ji, Jun, Ma, Tao, Wu, Junwei, Shangguan, Chengfang, Zhu, Zhenggang, Zhang, Jun

“…Abstract Background Efficacy of conventional sequential chemotherapy paradigm for advanced gastric cancer (AGC) patients has largely plateaued. Dynamic…”
Get full text

Prognostic value of clinicopathological characteristics in patients with pancreatic cancer by Geng, Mei, Xu, Haoping, Ren, Ruobing, Qu, Qing, Shangguan, Chengfang, Wu, Junwei, Jiang, Jinsong, Li, Hao, Cao, Weiguo

“…Background： The purpose of this study was to analyze the effects of all clinical characteristics on the overall survival time, in order to provide a basis for…”
Get full text

Value of 68Ga-FAPI-04 and 18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer by Miao, Ying, Feng, Runhua, Yu, Teng, Guo, Rui, Zhang, Min, Wang, Yue, Hai, Wangxi, Shangguan, Chengfang, Zhu, Zhenggang, Li, Biao

“…This prospective study investigated whether PET parameters from 18F-FDG and 68Ga-fibroblast activation protein inhibitor (FAPI)-04 PET/CT can predict a…”
Get full text

68Ga-FAPI-04 Positron Emission Tomography Distinguishes Malignancy From 18F-FDG-Avid Colorectal Lesions by Shangguan, Chengfang, Yang, Chen, Shi, Zhaopeng, Miao, Ying, Hai, Wangxi, Shen, Yan, Qu, Qing, Li, Biao, Mi, Jun

“…PURPOSELesions with a high uptake of 18F-fluorodeoxyglucose (18F-FDG) on positron emission tomography-computed tomography (PET-CT) can be benign and malignant…”
Get full text

Value of 68 Ga-FAPI-04 and 18 F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer by Miao, Ying, Feng, Runhua, Yu, Teng, Guo, Rui, Zhang, Min, Wang, Yue, Hai, Wangxi, Shangguan, Chengfang, Zhu, Zhenggang, Li, Biao

Get full text

Utility of [68Ga]FAPI-04 and [18F]FDG dual-tracer PET/CT in the initial evaluation of gastric cancer by Miao, Ying, Feng, Runhua, Guo, Rui, Huang, Xinyun, Hai, Wangxi, Li, Jian, Yu, Teng, Qu, Qian, Zhang, Min, Shangguan, Chengfang, Mi, Jun, Zhu, Zhenggang, Li, Biao

“…Objectives We aimed to investigate the role of [ 68 Ga]FAPI-04 and [ 18 F]FDG dual-tracer PET/CT for the initial assessment of gastric cancer and to explore…”
Get full text

Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001) by Zhou, Chenfei, Wu, Junwei, Yan, Jun, Wang, Chun, Mao, Yong, Tang, Xinyu, Zhu, Lingjun, Chen, Jun, Wang, Chunbing, Qin, Zhiquan, Han, Zhengxiang, Shangguan, Chengfang, Zhang, Jun

“…e16268 Background: Patients (pts) with advanced gastrointestinal (GI) tumors, such as colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC),…”
Get full text

Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of [CD8.sup.+] T cells by Jiang, Xinyi, Lin, Jian, Shangguan, Chengfang, Wang, Xiaoyao, Xiang, Bin, Chen, Juan, Guo, Hezhou, Zhang, Wu, Zhang, Jun, Shi, Yan, Zhu, Jiang, Yang, Hui

“…Antitumor activity of [CD8.sup.+] T cells is potentially restrained by a variety of negative regulatory pathways that are triggered in the tumor…”
Get full text

Modulation of lipid metabolism associated with response to metronomic capecitabine plus camrelizumab in patients with refractory gastrointestinal cancer: A prospective, single-center, exploratory trial by Zhou, Chenfei, Yin, Yuanyuan, Shangguan, Chengfang, Shi, Min, Cai, Qu, Ji, Jun, Zhang, Xuekun, Sun, Yan, Rensen, Sander S.M., Olde Damink, Steven W.M., Zhu, Zhenggang, Zeng, Rong, Zhang, Jun

“…2616 Background: Metronomic chemotherapy which can modulate tumor microenvironment is a potential partner of PD-1 antibodies. The association between lipid…”
Get full text

Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C by Wu, Junwei, Zhou, Chenfei, Yan, Jun, Han, Zhengxiang, Wang, Chun, Qin, Zhiquan, Jiang, Jinling, Wang, Chunbing, Tang, Xinyu, Zhu, Lingjun, Chen, Jun, Mao, Yong, Zhu, Liangjun, Wei, Xiaowei, Shangguan, Chengfang, Zhang, Jun

“…e16304 Background: Advanced gastrointestinal (GI) tumors, such as colorectal, gastric and pancreatic cancers (CRC, GC, and PC), and esophageal squamous cell…”
Get full text

Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C by Wu, Junwei, Zhou, Chenfei, Yan, Jun, Han, Zhengxiang, Wang, Chun, Qin, Zhiquan, Jiang, Jinling, Wang, Chunbing, Tang, Xinyu, Zhu, Lingjun, Chen, Jun, Mao, Yong, Wei, Xiaowei, Shangguan, Chengfang, Zhang, Jun

“…653 Background: Advanced gastrointestinal (GI) tumors, such as colorectal, gastric and pancreatic cancers (CRC, GC, and PC), and esophageal squamous cell…”
Get full text

A phase Ib, open-label, multi-cohort study of metronomic capecitabine plus camrelizumab for treatment of refractory solid tumor: McCrest trial by Zhou, Chenfei, Shangguan, Chengfang, Xi, Wenqi, Yang, Hui, Guo, Liting, Shi, Min, Cai, Qu, Ji, Jun, Shi, Yan, Liu, Jing, Zhu, Zhenggang, Zhang, Jun

“…e16079 Background: The efficacy of immune checkpoint inhibitors (ICIs) monotherapy for refractory solid tumor is relatively poor. Combination therapy is an…”
Get full text

Optimizing the program of sequential chemotherapy for advanced gastric cancer based on gene-level CNVs called from ctDNA by Xi, Wenqi, Zhou, Chenfei, Zhang, Shouwei, Yi, Zhao, Chen, Yawei, Ji, Jun, Ma, Tao, Wu, Junwei, Shangguan, Chengfang, Zhu, Zhenggang, Zhang, Jun

“…Abstract only e16068 Background: Tumor evolutionary trade-offs under treatment pressure can be utilized to optimize therapy. We aimed to profile the dynamic…”
Get full text

The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer by Yang, Chen, Shangguan, Chengfang, Lou, Guyin, Qu, Qing

Get full text

The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases by Gan, Guifang, Shi, Zhaopeng, Shangguan, Chengfang, Zhang, Jieying, Yuan, Yuan, Chen, Lei, Liu, Weiren, Li, Biao, Meng, Songshu, Xiong, Wujun, Mi, Jun

“…: Sorafenib is the only FDA-approved first-line target drug for HCC patients. However, sorafenib merely confers 3-5 months of survival benefit with less than…”
Get full text

Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001) by Liu, Jing, Wu, Junwei, Zhu, Liangjun, Yan, Jun, Mao, Yong, Tang, Xinyu, Zhu, Lingjun, Jiang, Hong, Wei, Xiaowei, Shangguan, Chengfang, Xi, Wenqi, Shi, Yan, Shi, Min, Zhou, Chenfei, Yang, Hui, Zhang, Jun

“…Abstract only TPS229 Background: Liver metastases (LMs) are usually found in gastrointestinal tumors, such as colorectal cancer (mCRC), esophageal squamous…”
Get full text